amended in connection with the rulemaking to fully implement mandated electronic filing on the EDGAR system for registrants whose filings are processed by the Divisions of Corporation Finance and Investment Management and for those making filings with respect to such registrants. Development and implementation of the EDGAR system was effected pursuant to Section 35A of the Securities Exchange Act of 1934 (15 U.S.C. 78*ll*).

Need for Corrections

This action is necessary to correct an internal cross reference within Form 8–A, for registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. 15 U.S.C. 78*l*(b) or (g).

Correction of Publication

Accordingly, the publication on December 30, 1994 of the final EDGAR rules, which were the subject of FR Doc. 94–31579, is corrected as follows:

1. On page 67765, second column, the amendatory language for amendment No. 35 is corrected to read as follows:

''35. By amending Form 8–A (referenced in § 249.208a), Instruction II.2 of Instructions as to Exhibits, by revising the phrase 'pursuant to Instruction 3 above' to read 'pursuant to Instruction II.1, above,'.''

Dated: January 9, 1995.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 95–912 Filed 1–12–95; 8:45 am]

BILLING CODE 8010–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Neomycin Sulfate Oral Solution

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Phoenix Scientific, Inc. The ANADA provides for use of a generic neomycin sulfate oral solution in the drinking water and milk for cattle (excluding veal calves), swine, sheep, and goats for the treatment and control of colibacillosis.

EFFECTIVE DATE: January 13, 1995.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV–135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1643.

SUPPLEMENTARY INFORMATION: Phoenix Scientific, Inc., 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506–0457, filed ANADA 200–118, which provides for the use of neomycin oral solution (neomycin sulfate) in the drinking water and milk for cattle (excluding veal calves), swine, sheep, and goats for the treatment and control of colibacillosis (bacterial enteritis) caused by *Escherichia coli* susceptible to neomycin sulfate. Approval of ANADA 200–118 is as a generic copy of the Upjohn Co.'s approved NADA 11–315. The ANADA is approved as of November 29, 1994, and 21 CFR 520.1485(b) is amended to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In addition, the heading of the section is editorially revised to reflect the name of the product.

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

2. Section 520.1485 is amended by revising the section heading and paragraph (b) to read as follows:

§ 520.1485 Neomycin sulfate oral solution.

* * * * *

(b) *Sponsors*. See Nos. 000009 and 059130 in § 510.600(c) of this chapter.

* * * * *

Dated: January 3, 1995.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 95–899 Filed 1–12–95; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Part 558

New Animal Drugs For Use In Animal Feeds; Salinomycin In Combination

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the approval of three abbreviated new animal drug applications (ANADA's) filed by Hoechst-Roussel Agri-Vet Co. The ANADA's provide for using approved Type A medicated articles to make Type C medicated broiler feeds containing salinomycin with chlortetracycline and roxarsone, or salinomycin with chlortetracycline, or salinomycin with oxytetracycline.

EFFECTIVE DATE: January 13, 1995.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for Veterinary Medicine (HFV–135), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1643.

SUPPLEMENTARY INFORMATION: Hoechst-Roussel Agri-Vet Co., P.O. Box 2500, Somerville, NJ 08876–1258, filed the following ANADA's:

ANADA 200–091, salinomycin with chlortetracycline and roxarsone, which provides for using approved single ingredient Type A medicated articles to make Type C medicated broiler feeds containing 40 to 60 grams per ton (g/t) salinomycin sodium activity, chlortetracycline calcium complex equivalent to 500 g/t chlortetracycline hydrochloride, and 45.4 g/t roxarsone for prevention of coccidiosis and as an aid in reduction of mortality due to certain *Escherichia coli* infections.

ANADA 200–095, salinomycin with chlortetracycline, which provides for using approved single ingredient Type A medicated articles to make Type C medicated broiler feeds containing 40 to 60 g/t salinomycin sodium activity with

chlortetracycline calcium complex equivalent to 500 g/t chlortetracycline hydrochloride for prevention of coccidiosis and as an aid in the reduction of mortality due to certain *E. coli* infections.

ANADA 200–096, salinomycin with oxytetracycline, which provides for using approved single ingredient Type A medicated articles to make Type C medicated broiler feeds containing 40 to 60 g/t salinomycin sodium activity with 500 g/t oxytetracycline for prevention of coccidiosis and as an aid in the reduction of mortality due to airsacculitis caused by certain strains of *E. coli*.

ANADA's 200–091 and 200–095 are approved as generic copies of American Cyanamid's NADA's 140–867 and 140–859. ANADA 200–096 is approved as a generic copy of Pfizer's NADA 140–448. ANADA 200–091 is approved as of January 13, 1995. ANADA's 200–095 and 200–096 are approved as of November 25, 1994. The regulations are amended in §§ 558.450 and 558.550 (21 CFR 558.450 and 558.550) to reflect the approvals.

These approvals are for use of Type A medicated articles to make Type C medicated feeds. Roxarsone is a Category II drug which, as in 21 CFR 558.4, requires an approved Form FDA 1900 for making a Type C medicated feed. Use of salinomycin, chlortetracycline, and roxarsone to make Type C medicated feeds as in ANADA 200–091 requires an approved Form FDA 1900.

FDA has published several documents amending § 558.550(a) to create paragraphs (a)(1) and (a)(2) and add a series of amendments to paragraph (a)(2). At this time, FDA is editorially amending the regulation following addition of these approvals to simplify the text.

In addition, FDA provided for the use of 45 and 45.4 g/t of roxarsone in this regulation. Those used at 45 g/t are amended to read 45.4 g/t.

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of these applications may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.24(d)(1)(ii) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

§ 558.450 [Amended]

2. Section 558.450 *Oxytetracycline* is amended in paragraph (d)(1), in table 1, under the heading ''Sponsor,'' in entry (v) for ''Salinomycin 40 to 60,'' by removing ''000069'' and adding in its place ''000069, 012799''.

3. Section 558.550 is amended by revising paragraph (a)(2) and by amending paragraph (b)(1)(ii)(*a*) and (b)(1)(xv)(*a*) by removing ''45'' and adding in its place ''45.4'' to read as follows:

§ 558.550 Salinomycin.

(a) * * *

(2) To 012799 for use as in paragraphs (b)(1)(i), (b)(1)(iii) through (b)(1)(xvi), and (b)(3)(i) through (b)(3)(iii) of this section.

* * * * *

Dated: January 4, 1995.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 95–898 Filed 1–12–95; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF JUSTICE

28 CFR Part 36

Nondiscrimination on the Basis of Disability by Public Aaccomodations and in Commercial Facilities

CFR Correction

In Title 28 of the Code of Federal Regulations, parts 0 to 42, revised as of July 1, 1994, appendix A to part 36 is corrected as follows:

1. On page 544, section 4.30.4, the first sentence is amended by adding the words ''(0.8 mm) minimum'' after ''1/32 in''.

2. On page 554, section 7.3, paragraph (1), the third entry in the first column of the table is revised to read ''9—15''.

BILLING CODE 1505–01–D

PENSION BENEFIT GUARANTY CORPORATION

29 CFR Parts 2610 and 2622

Late Premium Payments and Employer Liability Underpayments and Overpayments; Interest Rate for Determining Variable Rate Premium; Amendments to Interest Rates

AGENCY: Pension Benefit Guaranty Corporation.

ACTION: Final rule.

SUMMARY: This document notifies the public of the interest rate applicable to late premium payments and employer liability underpayments and overpayments for the calendar quarter beginning January 1, 1995. This interest rate is established quarterly by the Internal Revenue Service. This document also sets forth the interest rates for valuing unfunded vested benefits for premium purposes for plan years beginning in November 1994 through January 1995. These interest rates are established pursuant to section 4006 of the Employee Retirement Income Security Act of 1974, as amended. The effect of these amendments is to advise plan sponsors and pension practitioners of these new interest rates.

EFFECTIVE DATE: January 1, 1995.

FOR FURTHER INFORMATION CONTACT: Harold J. Ashner, Assistant General Counsel, Office of the General Counsel, Pension Benefit Guaranty Corporation, 1200 K Street, NW., Washington, DC 20005–4026; telephone 202–326–4024 (202–326–4179 for TTY and TTD). These are not toll-free numbers.

SUPPLEMENTARY INFORMATION: As part of title IV of the Employee Retirement Income Security Act of 1974, as amended (''ERISA''), the Pension Benefit Guaranty Corporation (''PBGC'') collects premiums from ongoing plans to support the single-employer and multiemployer insurance programs. Under the single-employer program, the PBGC also collects employer liability from those persons described in ERISA section 4062(a). Under ERISA section 4007 and 27 CFR 2610.7, the interest rate to be charged on unpaid premiums is the rate established under section 6601 of the Internal Revenue Code (''Code''). Similarly, under 29 CFR 2622.7, the interest rate to be credited or